New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control
Recruiting now
This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to…
Phase: PHASE1, PHASE2 • Sponsor: C Ray Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC